Palmar plantar erythrodysesthesia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
{{Palmar plantar erythrodysesthesia}}
{{Palmar plantar erythrodysesthesia}}
{{CMG}}, '''Associate Editor(s)-in-Chief:''' Zain Fatiwala, M.D.
{{CMG}}; {{AE}}
==Overview==
==Overview==
PPE occurs in 6-42% of patients receiving chemotherapy.<ref name="pmid20614462" /> In BMT patients, there is a 35% incidence of PPE and may be due to the use of high doses of chemotherapy with addition of total body irradiation.<ref name="pmid3527075">{{cite journal| author=Crider MK, Jansen J, Norins AL, McHale MS| title=Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 9 | pages= 1023-7 | pmid=3527075 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3527075  }}</ref>


Significant data has not shown and existence of association of PPE with race and or population groups.<ref name="pmid17101468">{{cite journal| author=Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P| title=The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. | journal=Eur J Dermatol | year= 2006 | volume= 16 | issue= 5 | pages= 494-9 | pmid=17101468 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17101468  }}</ref>
==Epidemiology and Demographics==
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.


==Epidemiology and demographics==
===Prevalence===
PPE occurs in 6-42% of patients receiving chemotherapy.<ref name="pmid20614462">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446  }}</ref>
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


Several authors have reported that the incidence of PLD-associated hand and foot syndrome for patients with any grade of PPE is about 50% and for patients with grade 3 and grade 4 PPE the incidence is about 20%  for a PLD dose of 50 mg/m2 every 4 weeks <ref name="pmid14998846">{{cite journal| author=O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al.| title=Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. | journal=Ann Oncol | year= 2004 | volume= 15 | issue= 3 | pages= 440-9 | pmid=14998846 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14998846  }}</ref>, <ref name="pmid11454878">{{cite journal| author=Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ| title=Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. | journal=J Clin Oncol | year= 2001 | volume= 19 | issue= 14 | pages= 3312-22 | pmid=11454878 | doi=10.1200/JCO.2001.19.14.3312 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11454878  }}</ref>. According to evidence, it has been determined that a dose of 40 mg/m2 every 4 weeks is at present considered equally effective and less toxic. This has become a preferred dosage<ref name="pmid17229768">{{cite journal| author=Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G| title=Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). | journal=Ann Oncol | year= 2007 | volume= 18 | issue= 7 | pages= 1159-64 | pmid=17229768 | doi=10.1093/annonc/mdl477 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17229768  }}</ref>.
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].
 
===Age===
*Patients of all age groups may develop [disease name].
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.  
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].
 
===Race===
*There is no racial predilection to [disease name].
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
 
===Region===
*The majority of [disease name] cases are reported in [geographical region].
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


In BMT patients, there is a 35% incidence of PPE and may be due to the use of high doses of chemotherapy with addition of total body irradiation.<ref name="pmid35270752">{{cite journal| author=Crider MK, Jansen J, Norins AL, McHale MS| title=Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 9 | pages= 1023-7 | pmid=3527075 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3527075  }}</ref>
==References==
==References==
{{reflist|3}}
{{reflist|3}}

Revision as of 15:19, 26 June 2019

Palmar plantar erythrodysesthesia Microchapters

Home

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Palmar plantar erythrodysesthesia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Palmar plantar erythrodysesthesia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Palmar plantar erythrodysesthesia epidemiology and demographics

CDC on Palmar plantar erythrodysesthesia epidemiology and demographics

Palmar plantar erythrodysesthesia epidemiology and demographics in the news

Blogs on Palmar plantar erythrodysesthesia epidemiology and demographics

Directions to Hospitals Treating Palmar plantar erythrodysesthesia

Risk calculators and risk factors for Palmar plantar erythrodysesthesia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may develop [disease name].
  • The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
  • [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

Retrieved from "https://www.wikidoc.org/index.php?title=Palmar_plantar_erythrodysesthesia_epidemiology_and_demographics&oldid=1573526"